Novartis sells bladder treatment rights to Warner Chilcott

pharmafile | September 24, 2010 | News story | Sales and Marketing |  Enablex, Novartis, Warner Chilcott 

Novartis is to sell the US rights to market its overactive bladder treatment Enablex to Warner Chilcott.

Novartis will receive an upfront payment of $400 million for Enablex (darifenacin) from Warner Chilcott, with the potential for additional milestone payments of up to $20 million, but retains rights to the drug outside the US.

The deal relates to a long-standing agreement between Novartis and Procter & Gamble, dating back to 2005. Warner Chilcott bought out Procter & Gamble’s pharma division last year, and acquired with it the option to buy the Enablex rights.

Under the terms of the deal announced today, Warner Chilcott assumes rights to solely promote and develop Enablex for the US and also expects to manufacture Enablex for that market once it has been transferred to Warner Chilcott’s manufacturing facility.

Advertisement

Enablex was approved in the US in 2004 for the treatment of overactive bladder and launched in early 2005. The product is known as Emselex in other territories.

Andrew McConaghie

Related Content

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

Mosquito image

First malaria medicine for infants under 4.5kg receives approval

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …

The Gateway to Local Adoption Series

Latest content